Cerebrolysin: stroke-trial results and evidence limits
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain. Clinical research includes stroke rehabilitation, but results depend on the study and outcome. This evidence does not establish a general memory or focus enhancer for healthy people.
Identity and formulation
Cerebrolysin is not a single peptide with one sequence or molecular mass. Its mixture identity and manufacturing specifications are important to any comparison.
Cortexin and other brain-derived mixtures are separate preparations. A review that includes more than one mixture must identify which product contributed to each result.
What the studies show
One randomized rehabilitation trial reported improved arm-function outcomes, whereas another found no significant overall motor-function difference and a favorable result in a severe-impairment subgroup. A broader Cochrane assessment of acute stroke found no mortality benefit and identified a potential increase in nonfatal serious adverse events.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
Exploratory randomized double-blind CARS trial after stroke, with standardized rehabilitation Reading scope: PubMed abstract and bibliographic record; not full-text review |
Cerebrolysin was associated with better day-90 arm-function and global-status measures than placebo. | The authors called for confirmation in a larger trial. Findings concern rehabilitation after stroke, not cognition in healthy adults. |
| Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke.
Randomized placebo-controlled trial in 70 stroke patients receiving rehabilitation Reading scope: PubMed abstract and bibliographic record; not full-text review |
There was no significant overall motor-function difference between groups; patients with severe impairment showed a favorable subgroup result. | A subgroup benefit does not make the overall comparison positive or establish benefit for all stroke patients. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Both improvement from baseline and improvement beyond rehabilitation plus placebo can occur in the same study. Only the latter addresses the added value of the intervention.
The 2023 Cochrane review evaluated acute stroke trials with defined timing criteria. It found little or no difference in death and a potential increase in nonfatal serious adverse events. That synthesis is separate from a single positive rehabilitation endpoint; the different questions should remain visible.
Safety context
A favorable tolerability description in one small trial does not erase a safety signal from a wider evidence synthesis.
The reviewed findings do not establish the risk of prolonged use for healthy-person cognitive enhancement or the equivalence of another porcine-derived product.
Study exposure and units
Clinical exposures are described as a volume of a specified manufactured preparation. They cannot be converted directly into a milligram amount of an unknown peptide blend.
The timing after stroke and the accompanying rehabilitation were part of the interventions. Omitting those details makes a study course look more transferable than it is.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Check the exact preparation, composition standard, manufacturer identification and formulation rather than treating the name as a single pure peptide.
A percentage purity result for one component cannot authenticate the entire mixture or establish equivalence to the clinical material.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does the evidence consistently show better motor recovery?
No. The selected trials differ: one was positive on its main arm-function outcome, while another had a null overall comparison with a favorable severe-impairment subgroup.
Can stroke results justify a general nootropic claim?
No. A damaged nervous system receiving structured rehabilitation is a different population and setting from a healthy person seeking better concentration.
Sources
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. (PubMed abstract and bibliographic record; not full-text review)
- Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. (PubMed abstract and bibliographic record; not full-text review)
- Cochrane 2023: Cerebrolysin for acute ischaemic stroke (Review abstract and bibliographic record; secondary evidence, not counted as a new primary trial)